瑞普替尼

{{Infobox drug
| drug_name =
| INN =
| type =
| image = Ripretinib skeletal.svg
| width =
| alt =
| caption =

| pronounce = rip re' ti nib
| tradename = Qinlock
| Drugs.com =
| MedlinePlus =
| licence_CA =
| licence_EU =
| DailyMedID = Ripretinib
| licence_US =
| pregnancy_AU =
| pregnancy_AU_comment =
| pregnancy_US =
| pregnancy_US_comment =
| pregnancy_category= 禁忌
| dependency_liability =
| addiction_liability =
| routes_of_administration = 口服
| class =
| ATCvet =
| ATC_prefix = 無
| ATC_suffix =
| ATC_supplemental =

| legal_AU = S4
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA =
| legal_CA_comment =
| legal_DE =
| legal_DE_comment =
| legal_NZ =
| legal_NZ_comment =
| legal_UK =
| legal_UK_comment =
| legal_US = Rx-only
| legal_US_comment =
| legal_UN =
| legal_UN_comment =
| legal_status =

| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life =
| duration_of_action =
| excretion =

| CAS_number_Ref =
| CAS_number = 1442472-39-0
| CAS_supplemental =
| PubChem = 71584930
| PubChemSubstance =
| IUPHAR_ligand =
| DrugBank_Ref =
| DrugBank = DB14840
| ChemSpiderID_Ref =
| ChemSpiderID = 67886378
| UNII_Ref =
| UNII = 9XW757O13D
| KEGG_Ref =
| KEGG = D11353
| ChEBI_Ref =
| ChEBI =
| ChEMBL_Ref =
| ChEMBL = 4216467
| NIAID_ChemDB =
| PDB_ligand =
| synonyms = DCC-2618

| IUPAC_name = 3-{4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl}-1-phenylurea
| chemical_formula =
| C = 24 | H = 21 | Br = 1 | F = 1 | N = 5 | O = 2
| molecular_weight =
| SMILES = CCN1C(=O)C(=CC2=C1C=C(NC)N=C2)C1=C(Br)C=C(F)C(NC(=O)NC2=CC=CC=C2)=C1
| Jmol =
| StdInChI = 1S/C24H21BrFN5O2/c1-3-31-21-12-22(27-2)28-13-14(21)9-17(23(31)32)16-10-20(19(26)11-18(16)25)30-24(33)29-15-7-5-4-6-8-15/h4-13H,3H2,1-2H3,(H,27,28)(H2,29,30,33)
| StdInChI_comment =
| StdInChIKey = CEFJVGZHQAGLHS-UHFFFAOYSA-N
| density =
| density_notes =
| melting_point =
| melting_high =
| melting_notes =
| boiling_point =
| boiling_notes =
| solubility =
| sol_units =
| specific_rotation =
}}
瑞普替尼（Ripretinib）是一種用于治疗晚期胃腸道基質腫瘤的药物。該藥物最常见的副作用有脱发、疲倦、恶心、腹痛、便秘、肌肉痛、腹泻、食欲不振和呕吐。。

2020年5月，瑞普替尼在美国獲得上市許可。。

参考资料
更多阅读
*

外部链接
*
*
*